Buscar
Mostrando ítems 1-10 de 14
Prevalence of occult Hepatitis B in patients infected with the hepatitis C will be treated with oral direct acting antivirals
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2019)
Direct-acting antiviral agents for HCV-associated glomerular disease and the current evidence
(Molecular Diversity Preservation International, 2019-10)
Glomerular disease is an extra-hepatic manifestation of hepatitis C virus infection (HCV) and membranoproliferative glomerulonephritis is the most frequent glomerular disease associated with HCV. It occurs commonly in ...
Prevalence of occult Hepatitis B in patients infected with the hepatitis C will be treated with oral direct acting antivirals
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2019)
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies
Chronic hepatitis C virus (HCV) infection is major cause of decompensated cirrhosis and liver cancer. The advent of curative new antiviral therapies since year 2015 has dramatically improved the prognosis of HCV patients. ...
Viral hepatitis in persons living with HIV in the post-COVID era
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...
Insulin resistance reduction after sustained virological response with direct acting antiviral: Not every population improvesRedução da resistência à insulina após resposta virológica sustentada com agentes antivirais diretos: Nem toda população melhora
(2018-07-01)
Background – Hepatitis C virus (HCV) infection is a serious public health problem, that affects approximately 170 million people worldwide. Chronic HCV infection is associated with hepatic insulin resistance and an increased ...
Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney diseaseEficacia y seguridad de los antivíricos de acción directa para el VHC en la nefropatía crónica de leve a moderada
(Sociedad Española de Nefrología Dr Rafael Matesanz, 2019-06)
BACKGROUND AND AIMS:The advent of direct-acting antiviral agents promises to change the management of hepatitis C virus infection (HCV) in patients with chronic kidney disease (CKD), a patient group in which the treatment ...